CNSP News and Press, CNS Pharmaceuticals Inc. From 04/17/23

2023-04-17 10:02:16 ET Gainers: Prometheus Biosciences ( RXDX ) +69% . CNS Pharmaceuticals ( CNSP ) +53% . Revelation Biosciences ( REVB ) +29% . Windtree Therapeutics ( WINT ) +26% . Kiromic BioPharma ( KRBP ) +22% . Loser...

2023-04-17 08:21:00 ET CNS Pharmaceuticals ( CNSP ) +72% . Presto Automation ( PRST ) +55% . Prometheus Biosciences ( RXDX ) +70% soars 70%, Merck dips after ~$11B buyout deal. Dragonfly Energy  ( DFLI ) +49% . Kiromic BioPharma ( ...

2023-04-17 06:00:00 ET 3 Research Techniques for Investing in Penny Stocks Penny stocks, with their low price and high potential for growth, attract many investors seeking substantial returns. These low-priced stocks, typically trading below $5 per share, can offer incredible opportunit...

2023-04-16 06:00:00 ET 3 Methods for Buying Energy Penny Stocks Right Now The energy sector has long been a cornerstone of the global economy, and as the world continues to evolve, so too do the opportunities within this dynamic industry. Enter energy penny stocks : the gateway for ...

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially...

Dutch scientists have found that the majority of brain cancer patients who have repeated MRI scans of their brains in follow-up visits tolerate the sessions quite well. However, if given a choice, most cancer patients would avoid gadolinium-based contrast agents (GBCAs) in cases with diagnostic...

CNS Pharmaceuticals recently announced it had enrolled the first patient in Switzerland as part of its ongoing potentially pivotal global GBM trial The adaptive, multicenter, open-label, randomized controlled trial is evaluating Berubicin for the treatment of recurrent GBM, the most common prim...

2023-04-10 11:12:26 ET CNS Pharmaceuticals ( NASDAQ: CNSP ) said it had enrolled over 100 patients in trial to test its lead product candidate, Berubicin, to treat glioblastoma. The company had opened 43 clinical trial sites of the 60 sites selected across the U...

Enrollment continues to rapidly progress toward planned interim analysis expected in the third quarter of 2023 HOUSTON, TX / ACCESSWIRE / April 10, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of...

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of r...